在过去的十年中，通过开发针对 DNA 序列变异的治疗方法，癌症医学取得了显着进展。然而，同一基因型可能出现不同的细胞状态，这一事实阻碍了纯粹的基因治疗选择方法。在多细胞生物中，细胞状态异质性是由表观遗传过程驱动的，这些过程调节基于 DNA 的功能，例如转录；这些过程的破坏是癌症的一个标志，导致有缺陷的细胞状态的出现。单细胞技术的进步使我们能够量化肿瘤的表观基因组异质性并了解其机制，从而改变我们对表观基因组变化如何驱动癌症进化的认识。本综述探讨了表观基因组异质性和可塑性作为细胞状态的储存库，从而作为肿瘤进化的根源的观点。讨论了量化表观基因组异质性并探索其各种原因和后果的最佳实践，包括表观基因组重编程、随机变化和持久记忆。还讨论了限制表观基因组异质性的新治疗方法的设计，以限制癌症发生和进展的长期目标。© 2024。Springer Nature Limited。

In the past decade, remarkable progress in cancer medicine has been achieved by the development of treatments that target DNA sequence variants. However, a purely genetic approach to treatment selection is hampered by the fact that diverse cell states can emerge from the same genotype. In multicellular organisms, cell-state heterogeneity is driven by epigenetic processes that regulate DNA-based functions such as transcription; disruption of these processes is a hallmark of cancer that enables the emergence of defective cell states. Advances in single-cell technologies have unlocked our ability to quantify the epigenomic heterogeneity of tumours and understand its mechanisms, thereby transforming our appreciation of how epigenomic changes drive cancer evolution. This Review explores the idea that epigenomic heterogeneity and plasticity act as a reservoir of cell states and therefore as a source of tumour evolution. Best practices to quantify epigenomic heterogeneity and explore its various causes and consequences are discussed, including epigenomic reprogramming, stochastic changes and lasting memory. The design of new therapeutic approaches to restrict epigenomic heterogeneity, with the long-term objective of limiting cancer development and progression, is also addressed.© 2024. Springer Nature Limited.